Four versus six cycles of cyclophosphamide/doxorubicin or paclitaxel in adjuvant breast cancer

eagle-i ID

Resource Type

Properties

1. ClinicalTrials.gov url

   http://www.clinicaltrials.gov/ct2/show/NCT00041119?term=CALGB-40101&rank=1

2. Intervention

   Cyclophosphamide/doxorubicin

3. Intervention

   Paclitaxel

4. Intervention

   Antineoplastic combined chemotherapy

5. Resource Description

   It is not yet known whether giving cyclophosphamide together with doxorubicin is more effective than giving paclitaxel alone in treating breast cancer. This randomized phase III trial is studying cyclophosphamide and doxorubicin to see how well they work compared to paclitaxel in treating women with invasive breast cancer.

6. Additional Name

   Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study

7. Contact

   Berenberg, Jeffrey

8. PI

   Berenberg, Jeffrey

9. Topic

   breast cancer

10. Study Population

    Women 18 years and older with Histologically confirmed invasive carcinoma of the breast with 0-3 positive axillary lymph nodes

11. Funded by

    Cancer Trials Support Unit

12. Phase

    Phase 3 clinical trial

13. Performed by

    Clinical Protocol & Data Management Shared Resource